Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Recovery time 25% Improvement Relative Risk Hospitalization time -13% Viral clearance time 0% c19hcq.org Hong et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? PSM retrospective 30 patients in South Korea (Feb - Apr 2020) Faster recovery with HCQ (not stat. sig., p=0.45) Hong et al., PLOS ONE, doi:10.1371/journal.pone.0267645 Favors HCQ Favors control
Use of combined treatment of 3rd-generation cephalosporin, azithromycin and antiviral agents on moderate SARs-CoV-2 patients in South Korea: A retrospective cohort study
Hong et al., PLOS ONE, doi:10.1371/journal.pone.0267645
Hong et al., Use of combined treatment of 3rd-generation cephalosporin, azithromycin and antiviral agents on moderate.., PLOS ONE, doi:10.1371/journal.pone.0267645
May 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 25 hospitalized patients treated with cephalosporin, azithromycin, and HCQ, and 217 SOC patients in South Korea, reporting no significant differences. 5 patients receiving lopinavir/ritonavir and HCQ >5 days were excluded for unknown reasons. HCQ was typically initiated based on progression or side effects from another treatment. Conflicting results are reported. Table 2 indicates 15 CA/HCQ patients after matching, while Table S2 shows 25, and the Table 3 count is blank. S2 appears to incorrectly show before matching results, and the after matching results are missing in Table 3. 200mg HCQ bid.
recovery time, 24.9% lower, HR 0.75, p = 0.45, treatment 15, control 15, inverted to make HR<1 favor treatment, propensity score matching.
hospitalization time, 12.7% higher, HR 1.13, p = 0.75, treatment 15, control 15, inverted to make HR<1 favor treatment, propensity score matching.
viral clearance time, 0.5% lower, HR 1.00, p = 0.99, treatment 15, control 15, inverted to make HR<1 favor treatment, propensity score matching.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hong et al., 4 May 2022, retrospective, South Korea, peer-reviewed, 11 authors, study period 28 February, 2020 - 28 April, 2020.
Contact: kmedicsoon@pusan.ac.kr, thhwang@pusan.ac.kr, wsabf@naver.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: PLOS ONE RESEARCH ARTICLE Use of combined treatment of 3rd-generation cephalosporin, azithromycin and antiviral agents on moderate SARs-CoV-2 patients in South Korea: A retrospective cohort study a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 Wooyoung Hong1☯, Yu-Kyung Park2, Bong-Ok Kim2, Sung Kyu Park2, Jiin Shin3, SoonPyo Jang4, Hea-Woon Park2, Wonjong Yang2, Joonyoung Jang2, Soon-Woo Jang ID5,6☯*, Tae-Ho Hwang7,8* 1 Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, United States of America, 2 Korea Workers’ Compensation & Welfare Services Daegu Hospital, Buk-gu, Daegu, Republic of Korea, 3 School of Medicine, Seoul National University, Seoul, Republic of Korea, 4 Department of Oral and Maxillofacial Surgery, Division of Oral Pathobiological Science, Graduate School of Dental Medicine, Hokkaido University, Hokkaido, Japan, 5 Director of Bukha Public Health Center, Jangseong, Republic of Korea, 6 Pusan University, School of Medicine, Yangsan, Republic of Korea, 7 Department of Pharmacology, School of Medicine, Pusan National University, Yangsan, Republic of Korea, 8 Gene and Cell Therapy Research Center for Vessel-associated Diseases, School of Medicine, Pusan National University, Yangsan, Republic of Korea OPEN ACCESS Citation: Hong W, Park Y-K, Kim B-O, Park SK, Shin J, Jang S-P, et al. (2022) Use of combined treatment of 3rd-generation cephalosporin, azithromycin and antiviral agents on moderate SARs-CoV-2 patients in South Korea: A retrospective cohort study. PLoS ONE 17(5): e0267645. https://doi.org/10.1371/journal. pone.0267645 Editor: Giordano Madeddu, University of Sassari, ITALY ☯ These authors contributed equally to this work. * kmedicsoon@pusan.ac.kr (SWJ); thhwang@pusan.ac.kr (THH) Abstract Objectives To assess efficacy and safety of the combined treatment of antibiotics (3rd-generation cephalosporin and azithromycin) and antiviral agents (lopinavir/ritonavir or hydroxychloroquine) on moderate COVID-19 patients in South Korea. Received: September 9, 2021 Accepted: April 12, 2022 Methods Published: May 4, 2022 A retrospective cohort study of the 358 laboratory-confirmed SARS-CoV-2 (COVID-19) patients was conducted. 299 patients met inclusion criteria for analysis. Propensity score matching (PSM) and Cox regression method were used to control and adjust for confounding factors. Mild to moderate COVID-19 patients were managed with either CA/LoP (cephalosporin, azithromycin, and lopinavir/ritonavir) (n = 57), CA/HQ (cephalosporin, azithromycin, and hydroxychloroquine) (n = 25) or standard supportive care (n = 217). We analyzed the association between treatment group and standard supportive group in terms of three endpoints: time to symptom resolution, time to viral clearance, and hospital stay duration. Using propensity-score matching analysis, three rounds of propensity-matching analysis were performed to balance baseline characteristics among three cohorts. Copyright: © 2022 Hong et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability Statement: Data Availability: Data cannot be shared publicly because use of the data was only approved by the ethics committee for use in this study. (IRB No.: 05-2020-082). A deidentified dataset and a data dictionary used in the analyses..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit